I don't think that a number of patents related to preclinical work/compounds would cause much in the way of business complication that would stand of the way of a sale, but who knows for sure without specifics. From what I've seen in the past, many biotechs that have been sold possess patents/compounds that are in addition to their lead compound. I guess we shall see with Zenith, I just hope management can do some business that recognizes the value that would appear to be in the company.